search
Back to results

Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
Slovakia
Study Type
Interventional
Intervention
Sonolysis
Sham procedure
Sponsored by
University Hospital Ostrava
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Coronary Artery Disease focused on measuring sonolysis, brain infarction, coronary angioplasty

Eligibility Criteria

35 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age 35-90 years
  • sufficient temporal bone window for TCD with detectable blood flow in MCA
  • independent patient (modified Rankin score 0-2)
  • informed consent signed by the patient
  • coronary angioplasty and stenting will be performed as an elective procedure

Exclusion Criteria:

  • contra-indication for MRI examination (pace-maker, implanted metal material, claustrophobia)
  • emergent coronary angioplasty and stenting

Sites / Locations

  • University Hospital Nitra

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Sonolysis

placebo

Arm Description

continual transcranial Doppler monitoring with maximal intensity during endovascular procedure

sham transcranial Doppler monitoring during endovascular procedure

Outcomes

Primary Outcome Measures

New infarction
New brain infarction detected using magnetic resonance diffusion weighted images (MRI-DWI)

Secondary Outcome Measures

Cognitive functions changes, measured by ADAS, MMSE, Clock Drawing Test and Verbal Fluency Test
Cognitive decline measured by ADAS, MMSE, Clock Drawing Test and Verbal Fluency Test
Large new infarction, infarction ≥0.5 mL detected using magnetic resonance diffusion weighted images (MRI-DWI)
New brain infarction ≥0.5 mL detected using magnetic resonance diffusion weighted images (MRI-DWI)
Volume of new brain infarction, detected using magnetic resonance diffusion weighted images (MRI-DWI)
Volume of new brain infarctions detected using magnetic resonance diffusion weighted images (MRI-DWI)
30-days morbidity and mortality
stroke, TIA, myocardial infarctions and death during 30 days after intervention
Symptomatic intracerebral hemorrhage, detected using magnetic resonance (MRI)
Intracerebral hemorrhage with worsening of neurological status (≥ 4 points in NIHSS scale) detected using magnetic resonance (MRI)

Full Information

First Posted
November 23, 2014
Last Updated
March 22, 2018
Sponsor
University Hospital Ostrava
search

1. Study Identification

Unique Protocol Identification Number
NCT02351050
Brief Title
Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting
Official Title
Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
April 2015 (Actual)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
November 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital Ostrava

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the project is to demonstrate a fibrinolytic effect of sonothrombolysis (continual transcranial Doppler monitoring) using 2 MHz diagnostic probe on the reduction of risk of brain infarctions due to the activation of endogenous fibrinolytic system during angioplasty and stenting of coronary arteries. 120 patients indicated for coronary angioplasty and stenting will be enrolled into the study in order to demonstrate a twenty-percent risk reduction of number and volume of brain infarctions detected using MRI examination 24 hours after cardiac endovascular treatment in 5% level of significance. Patients will be randomized - subgroup 1 will undergo a 40-240 minute non-diagnostic TCD monitoring during endovascular procedure, subgroup 2 will undergo interventions without TCD monitoring. Confirmation of our hypothesis that sonothrombolysis is able to activate endogenous fibrinolytic system during coronary angioplasty and stenting with consecutive reduction of the number and volume of brain infarcts, can lead to the increase of the safety these patients. We can presume that up to 50% of patients indicated for endovasular heart treatment can be treated using these methods in the future.
Detailed Description
AIM OF THE PROJECT The aim of the project is to demonstrate an effect of continual TCD monitoring using 2 MHz diagnostic probe with maximal diagnostic energy on the reduction of risk of brain microinfarctions due to the activation of endogenous fibrinolytic system and mechanical effect on emboli during coronary stenting. HYPOTHESIS Sonothrombolysis lead to activation of fibrinolytic system in both healthy volunteers and acute stroke patients. In acute stroke patients, mechanical effect of sonothrombolysis is the second effect leading to acceleration of occluded artery recanalization. We hypothesize that combination of mechanical effect and activation of fibrinolytic system during sonothrombolysis (TCD monitoring) during coronary stenting will lead to recanalization of small arterial occlusions caused by microembolization during intervention. The result will be reduction of volume and the number of brain infarctions. 120 patients indicated for coronary stenting will be enrolled into the study in order to demonstrate a twenty-percent risk reduction of number and volume of brain infarctions detected using MRI examination 24 hours after procedure in 5% level of statistical significance. Patients will be randomized into 2 subgroups. Subgroup 1 will undergo non-diagnostic bilateral TCD monitoring during coronary stenting. Subgroup 2 will undergo coronary stenting without TCD monitoring. PATIENTS AND METHODS Patients: 120 patients indicated for coronary angioplasty and stenting will be enrolled into the study during a 3-year period. All 120 patients will be randomized for standard coronary angioplasty and stenting and TCD monitored. Clinical examinations: Physical and neurological examinations including evaluating of neurological impairment of neurological deficit in NIHSS scale, modified Rankin scale and cognitive testing (Mini Mental State Examination, Clock drawing test) will be performed before and 24 - 72 hours after coronary angioplasty and stenting. Randomization: Randomization using computer generated random allocation will be used. Sonothrombolysis: In patients randomized into sonothrombolysis subgroup, bilateral MCA segment in depth 55 mm will be monitored for 40 - 240 minutes using a diagnostic 2 MHz probe with maximal diagnostic energy. Non-diagnostic TCD monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. The second (control) subgroup will undergo a standard coronary angioplasty and stenting without sonothrombolysis. MRI protocol will consists of 4 sequences: 1. Localizer; 2. T2TSE; 3. FLAIR; 4. DWI. Sequences 1-3 will be applied in the same level, they will have the same slice thickness and the same cut number. The slice thickness comprises its own cut thickness (5 mm) + distant factor (30%). Standard number of slices is 19. Standard slice level is considered to be a modified level of skull base due to the minimalization of distant artifacts EPI sequence. T2TSE: TR=4000/TE=99/ETL=9, FOV 230, FOV ph. 75%, matrix 256x256. FLAIR: 8050/112/ETL=21/2 conc., FOV 230, FOV ph. 76,6%, matrix 256x151. EPI-DWI: 4200/139/EPI f.=96/6 av., FOV 230, FOV ph. 100%, phase enc. direction A-P, matrix 128x96 with interpolation, phase partial Fourier 6/8, Bw 1346 Hz/Px, echo spacing 0.83 ms, TA. Sequence called "trace" with three types of MR pictures in every slice: (a) T2*EPI b=0; (b) DWI b=500; (c) DWI b=1000. The fourth type of images automatically created an ADC map (in-line postprocessing). DWI show a middle (average) diffusivity of every point of examined brain tissue when b value is 500 and 1000. This sequence is applied in order to assess hemorrhage (T2*EPI) and monitor sites of reduced diffusion (DWI, b=500 and 1000). New infarctions will be evaluated in the all of brain territories. Adverse effects: All adverse effects during 1 month after UM will be registered, especially all causes for new admissions to the hospital, worsening of neurological symptoms (>4 points in NIH stroke scale), brain edema, symptomatic and asymptomatic intracranial bleeding detected in control brain MRI. Study protocol has been approved by the Ethics Committees in accordance with the principles and guidelines of the Declaration of Helsinki, 1975.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
sonolysis, brain infarction, coronary angioplasty

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
144 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sonolysis
Arm Type
Experimental
Arm Description
continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
sham transcranial Doppler monitoring during endovascular procedure
Intervention Type
Device
Intervention Name(s)
Sonolysis
Other Intervention Name(s)
sonothrombolysis, sonothrombotripsy
Intervention Description
continual transcranial Doppler monitoring of middle cerebral artery
Intervention Type
Other
Intervention Name(s)
Sham procedure
Intervention Description
sham transcranial Doppler monitoring of middle cerebral artery
Primary Outcome Measure Information:
Title
New infarction
Description
New brain infarction detected using magnetic resonance diffusion weighted images (MRI-DWI)
Time Frame
24 hours after intervention
Secondary Outcome Measure Information:
Title
Cognitive functions changes, measured by ADAS, MMSE, Clock Drawing Test and Verbal Fluency Test
Description
Cognitive decline measured by ADAS, MMSE, Clock Drawing Test and Verbal Fluency Test
Time Frame
7 and 30 days after interventions
Title
Large new infarction, infarction ≥0.5 mL detected using magnetic resonance diffusion weighted images (MRI-DWI)
Description
New brain infarction ≥0.5 mL detected using magnetic resonance diffusion weighted images (MRI-DWI)
Time Frame
24 hours after intervention
Title
Volume of new brain infarction, detected using magnetic resonance diffusion weighted images (MRI-DWI)
Description
Volume of new brain infarctions detected using magnetic resonance diffusion weighted images (MRI-DWI)
Time Frame
24 hours after intervention
Title
30-days morbidity and mortality
Description
stroke, TIA, myocardial infarctions and death during 30 days after intervention
Time Frame
30 days after intervention
Title
Symptomatic intracerebral hemorrhage, detected using magnetic resonance (MRI)
Description
Intracerebral hemorrhage with worsening of neurological status (≥ 4 points in NIHSS scale) detected using magnetic resonance (MRI)
Time Frame
24 hours after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age 35-90 years sufficient temporal bone window for TCD with detectable blood flow in MCA independent patient (modified Rankin score 0-2) informed consent signed by the patient coronary angioplasty and stenting will be performed as an elective procedure Exclusion Criteria: contra-indication for MRI examination (pace-maker, implanted metal material, claustrophobia) emergent coronary angioplasty and stenting
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Skoloudik, MD, Prof
Organizational Affiliation
University Hospital Ostrava
Official's Role
Study Chair
Facility Information:
Facility Name
University Hospital Nitra
City
Nitra
ZIP/Postal Code
70852
Country
Slovakia

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting

We'll reach out to this number within 24 hrs